Idelalisib

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 794 publications

Integrated Transcriptomic and Secretome Proteomic Analysis of Hyperglycemia-Stimulated Endothelial Cells and Screening of Target Compounds.

Integrated Transcriptomic and Secretome Proteomic Analysis of Hyperglycemia-Stimulated Endothelial Cells and Screening of Target Compounds.

Journal: Journal of visualized experiments : JoVE
Published: January 19, 2026

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Journal: Biochemical and biophysical research communications
Published: December 01, 2025

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.

Journal: British journal of haematology
Published: November 13, 2025

Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia.

Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia.

Journal: Toxicology and applied pharmacology
Published: October 16, 2025

In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia.

In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia.

Journal: Toxicology and applied pharmacology
Published: October 16, 2025

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Journal: Molecular oncology
Published: September 01, 2025

Recent Advances in One-Pot Multicomponent Reactions for the Synthesis of Substituted Quinazolin-4(3H)-ones.

Recent Advances in One-Pot Multicomponent Reactions for the Synthesis of Substituted Quinazolin-4(3H)-ones.

Journal: Molecules (Basel, Switzerland)
Published: August 14, 2025

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Journal: Hematology/oncology clinics of North America
Published: July 01, 2025

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report.

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report.

Journal: Cureus
Published: June 24, 2025

Inhibition of PI3K/AKT/mTOR signaling enhances autophagy in HL-60 acute myeloid leukemia cells: An integrative bioinformatic and in vitro study.

Inhibition of PI3K/AKT/mTOR signaling enhances autophagy in HL-60 acute myeloid leukemia cells: An integrative bioinformatic and in vitro study.

Journal: Biochemistry and biophysics reports
Published: May 29, 2025

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.

Journal: Oncoscience
Published: May 29, 2025

PLEKHG7 Expression: A Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma.

PLEKHG7 Expression: A Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma.

Journal: Protein and peptide letters
Published: April 10, 2025
Showing 1-12 of 794

Last Updated: 02/24/2026